PeptiDream Inc. (JP)

https://www.peptidream.com

whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate (PDC), and multi-functional peptide conjugates (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. *

	Start	2006-07-03 splitoff
	Predecessor	University of Tokyo
	Industry	Peptide Discovery Platform System (PDPS) technology
	Industry 2	peptide-based drug
	Person	Kubota, Kiichi (PeptiDream 201504 CEO)
	Person 2	Reid, Patrick (PeptiDream 202012 CEO)

	Region	Tokyo
	Country	Japan
	City	Kawasaki, Kanagawa
		Address record changed: 2024-05-07

Basic data	Employees	n. a.

		* Document for »About Section«: PeptiDream Inc.. (4/30/24). "Press Release: PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis". Kanagawa.

		Record changed: 2024-05-07